Sound Blade Medical develops handheld ultrasound-guided histotripsy technology designed to deliver non-invasive, non-thermal, and non-ionizing mechanical tissue ablation guided by real-time imaging. Its device induces cavitation bubbles with short, high-pressure ultrasound pulses so collapsing bubbles liquefy targeted tissue, which the company says may allow better immune and healing responses and avoid heat-related risks. The company positions histotripsy as offering potentially improved patient outcomes versus open surgery, including less blood loss, fewer complications, reduced recovery time, and decreased infection risk. Founded in 2023 and based in Halifax, Nova Scotia, Sound Blade plans to use new funding to accelerate development and clinical validation, expand its team, and pursue regulatory approvals. The company closed an oversubscribed US $16.5 million Series A to support those efforts. Jeremy Brown, Ph.D., is co-founder and CEO.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2025